Asia
Taiji Industry Gets China Supplementary Nod for Heart Failure Injection
China's drug regulator approved Chongqing Taiji Industry's (SHA:600129) supplementary drug application for its digoxin injection, according to a Saturday filing with the Shanghai bourse.The injection helps treat mild to moderate heart failure in adults and increases cardiac force in children with heart failure, the filing said.
SHA:600129
